Bisphosphonate Drug Global Market Report 2025

The bisphosphonate drug market size has grown strongly in recent years. It will grow from $4.98 billion in 2024 to $5.28 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. This expansion during the historical period was fueled by the rising incidence of osteoporosis, greater public awareness regarding bone health, widespread usage of drugs like alendronate and risedronate, a growing demographic of postmenopausal women, and increased demand for therapies related to bone cancer and metastasis.

The bisphosphonate drug market size is expected to see strong growth in the next few years. It will grow to $6.66 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The anticipated growth during the forecast period will be driven by the increased availability of generic bisphosphonates, a rapidly aging global population, higher detection rates of osteopenia, a surge in bone complications from cancer, proactive guidelines from regulatory bodies, and a heightened emphasis on preventive healthcare. Key emerging trends include the growing preference for oral formulations, innovations in drug delivery systems, the use of digital tools to engage patients, personalized treatment approaches based on genetic profiles, and the adoption of AI technologies for predictive health monitoring.

The rising incidence of osteoporosis is expected to drive the growth of the bisphosphonates drug market in the coming years. Osteoporosis is a condition marked by weakened bones that are more susceptible to fractures due to decreased bone density. The growing prevalence of osteoporosis is largely attributed to the aging global population, as bone density naturally declines with age, along with lifestyle factors and inadequate preventive care. Bisphosphonate drugs treat osteoporosis by slowing bone degradation, thereby strengthening bones and lowering the risk of fractures. For example, in August 2024, Healthy Bones Australia reported that in 2023, there were approximately 193,482 fractures associated with osteoporosis and osteopenia. This number is projected to increase by 34% to 237,632 fractures by 2033. As a result, the rising number of osteoporosis cases is fueling the growth of the bisphosphonates drug market.

Leading companies in the bisphosphonate drug market are emphasizing regulatory approvals to expand product access, enhance market competitiveness, and comply with evolving safety and efficacy standards. Regulatory approvals, granted by government health agencies, authorize companies to market and sell their drugs after confirming they are safe and effective. For instance, in March 2025, Celltrion, Inc., a biopharmaceutical firm based in South Korea, received U.S. FDA approval for its biosimilars STOBOCLO (denosumab-bmwo) and OSENVELT (denosumab-bmwo). STOBOCLO is approved for treating various osteoporosis-related conditions, including osteoporosis in postmenopausal women and men, glucocorticoid-induced osteoporosis, and bone loss from specific cancer treatments. OSENVELT, on the other hand, is indicated for cancer-related skeletal issues such as preventing bone complications in patients with multiple myeloma or bone metastases, treating giant cell tumor of bone, and managing malignancy-associated hypercalcemia.

In May 2023, Abiogen Pharma S.p.A., a pharmaceutical company based in Italy, acquired EffRx Pharmaceuticals SA for an undisclosed sum. This acquisition was aimed at strategically strengthening and diversifying Abiogen’s rare disease portfolio by incorporating EffRx’s innovative treatments for musculoskeletal and rare disorders. It also helps Abiogen expand its international reach and capabilities in developing and commercializing specialized therapies globally. EffRx Pharmaceuticals SA, located in Switzerland, is a specialty pharmaceutical firm that produces and markets bisphosphonate drugs for osteoporosis treatment.

Major players in the bisphosphonate drug market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries, Sun Pharmaceutical Industries Ltd., Apotex Inc., Aurobindo Pharma Ltd, Dr. Reddy's Laboratories Ltd., Cipla Ltd., Hikma Pharmaceuticals, Zydus Lifesciences Ltd., Alkem Laboratories, Natco Pharma Ltd., Strides Pharma, Radius Health Inc., EffRx Pharmaceuticals, Warner Chilcott, and Abiogen Pharma S.p.A.

North America was the largest region in the bisphosphonate drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in bisphosphonate drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the bisphosphonate drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Bisphosphonates are a class of medications that help prevent bone density loss. They are widely prescribed to manage or prevent osteoporosis and other bone-related conditions by inhibiting the processes that lead to bone degradation. The primary goal of bisphosphonates is to enhance bone strength and lower the risk of fractures, particularly in patients diagnosed with osteoporosis.

The principal types of bisphosphonate medications include alendronate, risedronate, and zoledronic acid. Alendronate is commonly used to prevent and treat osteoporosis by reducing bone resorption and promoting bone mass gain. These drugs are available in both oral and intravenous formulations and are distributed through hospital pharmacies, retail outlets, online pharmacies, and other channels. They are used for various indications, such as postmenopausal osteoporosis, male osteoporosis, Paget’s disease, cancer therapy-induced bone loss, glucocorticoid-induced osteoporosis, and more. The end users of these drugs include hospitals, clinics, home care environments, and other healthcare settings.

The bisphosphonate drug market research report is one of a series of new reports that provides bisphosphonate drug market statistics, including bisphosphonate drug industry global market size, regional shares, competitors with a bisphosphonate drug market share, detailed bisphosphonate drug market segments, market trends and opportunities, and any further data you may need to thrive in the bisphosphonate drug industry. This bisphosphonate drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bisphosphonate drug market consists of sales of products including oral tablets, bisphosphonate capsules, bisphosphonate injections, oral solutions, and intravenous (IV) infusions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.